LBH589 (Panobinostat), a potent pan-histone deacetylase (HDAC) inhibitor, has been approved by the United States Food and Drug Administration (FDA) for clinical use in the treatment of multiple myeloma [27,28]. Here, HDAC9 is linked to plasma cell myeloma.